Nexcital Tablet 5mg

Product Information

NEXCITAL

Nexcital®(Escitalopram)

Presentation

Nexcital-5 tablet: Green, parallel capsule shaped, film coated tablet; each tablet contains Escitalopram Oxalate INN equivalent to

Escitalopram 5 mg.

Nexcital-10 tablet: Yellow, parallel capsule shaped, film coated tablet; each tablet contains Escitalopram Oxalate INN equivalent

to Escitalopram 10 mg.

Indications

Escitalopram is indicated in patients with depressive illness and panic disorder.

Dosage and administration

Depressive illness: Adult: 10 mg (one Nexcital-10 tablet) once daily, increased if necessary to max. 20 mg (two Nexcital-10

tablets) daily.

Elderly: Initially half adult dose, lower maintenance dose may be sufficient. Child and adolescent under 18 years: Not

recommended.

Panic disorder: Adult: Initially 5 mg (one Nexcital-5 tablet) daily increased to 10 mg (one Nexcital-10 tablet) daily after 7

days; max. 20 mg (two Nexcital-10 tablets) daily.

Elderly: Lower maintenance dose may be sufficient.

Child and adolescent under 18 years: Not recommended.

Contra-Indications, warnings, etc.

Contra-indications: SSRIs should not be used if the patient enters a manic phase.

Precautions: SSRIs should be used with caution in patients with epilepsy (avoid if poorly controlled, discontinue if convulsions

develop), concurrent electroconvulsive therapy (prolonged seizures reported with fluoxetine), history of mania, cardiac disease,

diabetes mellitus, angle-closure glaucoma, concomitant use of drugs that increase risk of bleeding, history of bleeding disorders

(especially gastro-Intestinal bleeding), hepatic and renal impairment.

Drug Interactions: As SSRI or related antidepressant should not be started until 2 weeks after stopping an MAOI. Conversely, an

MAOI should not be started until at least a week after an SSRI or related antidepressant has been stopped (2 weeks in the case

of paroxetine and sertraline, at least 5 weeks in the case of fluoxetine).

Use in pregnancy and lactation: When treating a pregnant woman with Escitalopram during the third trimester, the physician should

carefully consider the potential risks and benefits of treatment. It is excreted in human breast milk. The decision whether

to continue or discontinue either nursing or Escitalopram therapy should take into account the risk of citalopram exposure for the

infant and the benefits Escitalopram treatment for the mother.

Side-effects: SSRIs are less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants.

Side-effects of the SSRIs include gastro-intestinal effects (dose related and fairly common-include nausea, vomiting, dyspepsia,

abdominal pain, diarrhoea, constipation), anorexia with weight loss (increased appetite and weight gain also reported) and

hypersensitivity reactions including rash, urticaria, angioedema, anaphylaxis, artharlgia, myalgia, and photosensitivity; other

side-effects include dry mouth, nervousness, anxiety, headache, insomnia, tremor, dizziness, asthenia, hallucinations, drowsiness,

convulsions, galactorrhoea, sexual dysfunction, urinary retention, sweating, hypomania or mania, movement disorders and

dyskinesias, visual disturbances.

Pharmaceutical precautions

Store in a cool and dry place, protected from light.

Package quantities

Nexcital-5 tablet: Cartons of 30 tablets in blister.

Nexcital-10 tablet: Cartons of 30 tablets in blister.